Literature DB >> 17278675

[Treatment retention and evolution of clientele in a low threshold methadone substitution treatment program in Montreal].

Michel Perreault1, Marie-Christine Héroux, Noé Djawn White, Pierre Lauzon, Céline Mercier, Michel Rousseau.   

Abstract

OBJECTIVES: To evaluate client treatment retention and evolution in terms of living conditions, at-risk behaviours, and the use of psychoactive substances (PAS) over a one-year period, following admission into a low-threshold methadone program in Montreal.
METHOD: Individual interviews were administered to 114 clients from Relais-Méthadone (RM) at admission and one year after treatment initiation. Participants reported on PAS consumption and unsafe practices of drug use and sexual behaviours at high risk for transmission of HIV, sexually transmitted infections (STI) and other blood-borne viruses (BBV). Services utilized by clients were documented from Relais-Méthadone files. Bivariate analyses were used to compare data recorded at admission and one-year follow-up.
RESULTS: The treatment retention rate after one year at RM was 64%. However, by taking into account those clients who were transferred to a regular program during the study period, as well as those who voluntarily tapered their methadone treatment (16.7%), the status of 80.7% of clients demonstrated improvement one year after admission into treatment. Furthermore, the clients who remained in treatment for a year for whom information was available (n = 60) showed a tendency towards more stable living conditions. They also demonstrated a significant decrease in both the number of PAS injections and in risky behaviours related to drug consumption. A statistically significant decrease in the frequency of heroine and cocaine use was also observed. By contrast, however, two thirds of the individuals in treatment after a year (n = 42) maintained or increased their daily consumption of other PAS. DISCUSSION: The treatment retention rate is comparable to other low or regular threshold substitution programs. The results support previous studies showing that the methadone substitution treatment reduces heroine and cocaine consumption, and decreases the number of unsafe behaviours that could potentially transmit HIV, STI and BBV for the majority of clients who remained in treatment. Future research could focus attention on people who abandon treatment and those who present at-risk behaviours during treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278675      PMCID: PMC6975673     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  19 in total

1.  Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study.

Authors:  M Gossop; J Marsden; D Stewart; A Rolfe
Journal:  Drug Alcohol Depend       Date:  2000-11-01       Impact factor: 4.492

2.  Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study.

Authors:  M Gossop; J Marsden; D Stewart; S Treacy
Journal:  AIDS Care       Date:  2002-02

3.  Reduction or cessation of injecting risk behaviours? Treatment outcomes at 1-year follow-up.

Authors:  Michael Gossop; John Marsden; Duncan Stewart; Tara Kidd
Journal:  Addict Behav       Date:  2003-06       Impact factor: 3.913

4.  The 'methadone by bus' project in Amsterdam.

Authors:  E C Buning; G H Van Brussel; G Van Santen
Journal:  Br J Addict       Date:  1990-10

5.  A framework for the evaluation of activities and programs with harm-reduction objectives.

Authors:  A C Ogborne; C Birchmore-Timney
Journal:  Subst Use Misuse       Date:  1999-01       Impact factor: 2.164

6.  Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence.

Authors:  Carol J Strike; William Gnam; Karen Urbanoski; Benedikt Fischer; David C Marsh; Margaret Millson
Journal:  Addict Behav       Date:  2005-06       Impact factor: 3.913

7.  Evaluation of a low-threshold clinic for opiate-dependent drug users.

Authors:  I W Ryrie; J Dickson; C Robbins; K Maclean; C Climpson
Journal:  J Psychiatr Ment Health Nurs       Date:  1997-04       Impact factor: 2.952

8.  [Accessibility to methadone substitution treatment: the role of a low-threshold program].

Authors:  Michel Perreault; Michel Rousseau; Céline Mercier; Pierre Lauzon; Carole Gagnon; Pierre Côté
Journal:  Can J Public Health       Date:  2003 May-Jun

9.  High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study.

Authors:  J Bruneau; F Lamothe; E Franco; N Lachance; M Désy; J Soto; J Vincelette
Journal:  Am J Epidemiol       Date:  1997-12-15       Impact factor: 4.897

10.  Differentiation in the Amsterdam methadone dispensing circuit: determinants of methadone dosage and site of methadone prescription.

Authors:  M W Langendam; H J van Haastrecht; G H van Brussel; H Reurs; A A van den Hoek; R A Coutinho; E J van Ameijden
Journal:  Addiction       Date:  1998-01       Impact factor: 6.526

View more
  7 in total

1.  Individual and structural vulnerability among female youth who exchange sex for survival.

Authors:  Cari L Miller; Sarah J Fielden; Mark W Tyndall; Ruth Zhang; Kate Gibson; Kate Shannon
Journal:  J Adolesc Health       Date:  2011-05-26       Impact factor: 5.012

2.  Provider views of harm reduction versus abstinence policies within homeless services for dually diagnosed adults.

Authors:  Benjamin F Henwood; Deborah K Padgett; Emmy Tiderington
Journal:  J Behav Health Serv Res       Date:  2014-01       Impact factor: 1.505

3.  The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; Suzanne Brissette; Jill Chettiar; Pascal Schneeberger; David C Marsh; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  J Urban Health       Date:  2008-08-29       Impact factor: 3.671

4.  Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; David C Marsh; Daphne Guh; Suzanne Brissette; Candice Gartry; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

5.  Methadone treatments in a Swiss region, 2001-2008: a registry-based analysis.

Authors:  Thérèse Huissoud; Valentin Rousson; Françoise Dubois-Arber
Journal:  BMC Psychiatry       Date:  2012-12-28       Impact factor: 3.630

6.  Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.

Authors:  Jamie Carter; Barry Zevin; Paula J Lum
Journal:  Addict Sci Clin Pract       Date:  2019-05-06

7.  Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment.

Authors:  Kristi Hill; Laura Nussdorf; Julia D Mount; Rachel Silk; Chloe Gross; David Sternberg; Phyllis Bijole; Miriam Jones; Randy Kier; Dana Mccullough; Poonam Mathur; Shyam Kottilil; Henry Masur; Sarah Kattakuzhy; Elana S Rosenthal
Journal:  J Addict Med       Date:  2022 Jan-Feb 01       Impact factor: 3.702

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.